At the end of the latest market close, Alnylam Pharmaceuticals, Inc. (ALNY) was valued at $117.96. In that particular session, Stock kicked-off at the price of $118.11 while reaching the peak value of $120.71 and lowest value recorded on the day was $118.11. The stock current value is $119.33.
Alnylam Pharmaceuticals, Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $125.72 on 12/06/19, with the lowest value was $65.81 for the same time period, recorded on 05/20/19.
Alnylam Pharmaceuticals, Inc. (ALNY) full year performance was 47.43%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Alnylam Pharmaceuticals, Inc. shares are logging -5.08% during the 52-week period from high price, and 81.33% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $65.81 and $125.72.
The company’s shares, operating in the sector of healthcare managed to top a trading volume set approximately around 248346 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the company recorded performance in the market was 2.42%, having the revenues showcasing 32.30% on a quarterly basis in comparison with the same period the last year. At the time of this writing, the total market value of the company is set at 13.01B, with the company having 1065 employees.
Alnylam Pharmaceuticals, Inc. (ALNY) in the eye of market guru’s
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 99.26, with a change in the price was noted +38.34. In a similar fashion, Alnylam Pharmaceuticals, Inc. posted a movement of +47.52% for the period of last 100 days, recording 697,563 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity. The total Debt to Equity ratio for ALNY is recording 0.00 concluded with the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Alnylam Pharmaceuticals, Inc. (ALNY): Stocks Technical analysis and Trends
Raw Stochastic average of Alnylam Pharmaceuticals, Inc. in the period of last 50 days is set at 81.82%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 68.87%. In the last 20 days, the company’s Stochastic %K was 55.19% and its Stochastic %D was recorded 53.92%.
If we look into the earlier routines of Alnylam Pharmaceuticals, Inc., multiple moving trends are noted. Price performance for year-to-date for the company’s stock appears to be pessimistic, given the fact the metric is recording 2.42%. Additionally, trading for the stock in the period of the last six months notably improved by 54.24%, alongside a boost of 47.43% for the period of the last 12 months. The shares increased approximately by 4.01% in the 7-day charts and went down by -0.11% in the period of the last 30 days. Common stock shares were driven by 32.30% for the with last recorded quarter.